SpineGuard completes bond financing to support deployment of new products.

SpineGuard Completes Bond Financing Agreement and Subscribes €100,000 to Support Commercialization of New Products

Paris & Boulder, Colo., January 07, 2025–(BUSINESS WIRE)–Regulatory News:

SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, announces the completion of a bond financing agreement of an amount up to €1 million and the subscription of 100.000 euros to support the commercialization of its two new products featuring DSG technology: Threaded PediGuard for anterior approach and PsiFGuard for sacroiliac joint fusion.

Threaded PediGuard for Anterior Approach Surgery

As announced on September 3, 2024, SpineGuard obtained the CE-MDR certification for its class IIa and Ir devices, enabling the launch of Threaded PediGuard, specifically designed for anterior spine surgery in Europe. New fusionless correction techniques have opened up a high-potential market segment experiencing rapid growth.

• These techniques allow earlier intervention for children suffering from scoliosis, offering a far less incapacitating surgical treatment while accommodating their growth.
• This innovative approach has been gaining traction worldwide, and SpineGuard is well-positioned to capitalize on this trend with its Threaded PediGuard technology.

PsiFGuard for Sacroiliac Fusion Co-Developed with Omnia Medical

On September 30, 2024, SpineGuard announced the 510k clearance by the FDA of its new PsiFGuard cannulated probe designed to secure sacroiliac implant placement. Since then, many cases have been performed with the device by various physicians and their feedback has been extremely positive.

• It confirms that PsiFGuard greatly facilitates the placement of Omnia’s implant into the optimal position for success within the sacroiliac joint.
• The collaboration between SpineGuard and Omnia Medical has resulted in a highly effective solution for sacroiliac fusion, addressing a significant unmet need in the field.

Amortized Bond Financing of an Amount of up to €1 Million

To support the market launch of Threaded PediGuard and PsiFGuard, SpineGuard has secured a bond financing with the Luxembourg-based fund, Hexagon Capital Fund, for a maximum amount of €1,000,000, with a received subscription of €100,000.

• Each bond, with a par value of €1,000, will mature at the end of a 24-month period from the issue date and will be amortized on a quarterly basis.
• The bonds will carry an annual interest of 12%, payable quarterly.
• SpineGuard will repay the principal and interest in cash but may retain the option to redeem the bonds in shares at its sole discretion, based on the delegation of authority granted by the sixteenth (16th) resolution of the Ordinary and Extraordinary General Meeting held on June 26, 2024.

SpineGuard Engages in Multiple ESG Initiatives

For further information, visit https://www.spineguard.com/.

Disclaimer:

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

View Source Version on Businesswire.com:

https://www.businesswire.com/news/home/20250107648060/en/

Contacts:

SpineGuard

• Pierre Jérôme – CEO & Chairman
  • Tel: +33 1 45 18 45 19
  • p.jerome@spineguard.com
• Anne-Charlotte Millard – CFO
  • Tel: 01 45 18 45 19
  • ac.millard@spineguard.com

NewCap

• Investor Relations & Financial Communication
  • Mathilde Bohin / Aurélie Manavarere
  • Tel: +33 1 44 71 94 94
  • spineguard@newcap.eu